close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Spherix Global Insights

< Previous 1 2 3 4 Next >
News headline image
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
From Spherix Global Insights
Via GlobeNewswire
News headline image
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
From Spherix Global Insights
Via GlobeNewswire
News headline image
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
From Spherix Global Insights
Via GlobeNewswire
News headline image
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
From Spherix Global Insights
Via GlobeNewswire
News headline image
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
From Spherix Global Insights
Via GlobeNewswire
News headline image
New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments
From Spherix Global Insights
Via GlobeNewswire
News headline image
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
From Spherix Global Insights
Via GlobeNewswire
News headline image
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
From Spherix Global Insights
Via GlobeNewswire
News headline image
Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
From Spherix Global Insights
Via GlobeNewswire
News headline image
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights' Tucker Hurtado Recognized as Luminary by Healthcare Businesswomen’s Association
From Spherix Global Insights
Via GlobeNewswire
News headline image
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
US Hematologists Show Cautious Optimism as Data Reveal Early Adoption Trends for Hympavzi (Pfizer) and Alhemo (Novo Nordisk) in Hemophilia A and B, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today